• LAST PRICE
    0.7151
  • TODAY'S CHANGE (%)
    Trending Down-0.0049 (-0.6806%)
  • Bid / Lots
    0.7101/ 1
  • Ask / Lots
    0.7200/ 3
  • Open / Previous Close
    0.7200 / 0.7200
  • Day Range
    Low 0.7000
    High 0.7200
  • 52 Week Range
    Low 0.5200
    High 7.7900
  • Volume
    25,510
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.72
TimeVolumeOCEA
09:32 ET11370.72
09:53 ET2750.700001
10:09 ET1000.71
10:11 ET3000.7051
10:20 ET2000.7076
10:22 ET28380.71255
10:24 ET105000.7125
10:31 ET2000.7051
10:56 ET1000.72
11:00 ET1360.71
11:02 ET10000.701
11:45 ET13160.7
11:56 ET1000.72
12:14 ET3000.7
12:15 ET2000.71
12:35 ET1000.7113
01:09 ET2500.717
01:33 ET2000.7151
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOCEA
Ocean Biomedical Inc
24.9M
-0.2x
---
United StatesABP
ABPRO Holdings Inc
25.0M
20.7x
---
United StatesCVKD
Cadrenal Therapeutics Inc
24.9M
-2.0x
---
United StatesCLCS
Cell Source Inc
24.9M
-3.2x
---
United StatesATHA
Athira Pharma Inc
24.7M
-0.2x
---
United StatesCTXR
Citius Pharmaceuticals Inc
25.8M
-0.6x
---
As of 2024-11-25

Company Information

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

Contact Information

Headquarters
515 Madison Ave Suite 8078NEW YORK, NY, United States 10022
Phone
646-908-2658
Fax
---

Executives

Executive Chairman of the Board, Founder
Chirinjeev Kathuria
Chief Executive Officer, Director
Michelle Berrey
Chief Financial Officer
Jolie Kahn
Executive Vice President, Head of External Innovation and Academic Partnerships, Secretary
Daniel Behr
Chief Accounting Officer, Assistant Secretary
Robert Sweeney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$24.9M
Revenue (TTM)
$0.00
Shares Outstanding
34.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.01
Book Value
$-0.32
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.